首页> 外文期刊>Clinical Medicine Insights: Gastroenterology >Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management
【24h】

Primary Sclerosing Cholangitis: Therapeutic Options and Surveillance Management

机译:原发性硬化性胆管炎:治疗选择和监测管理

获取原文
           

摘要

Primary sclerosing cholangitis is a chronic immune-mediated liver disease. Though rare, it poses several clinical concerns for the managing physician. There are currently limited therapeutic options in the management of the condition and weak evidence base behind them. Endoscopic intervention is limited to those patients with obstructing stricture-related disease, and even liver transplantation has a risk of disease recurrence. Surveillance for inflammatory bowel disorders, metabolic bone disease, and malignancy is paramount when managing such patients. This article provides an overview of the condition with further focus on current therapeutic options and guidance on surveillance management.
机译:原发性硬化性胆管炎是一种慢性免疫介导的肝病。尽管很少见,但它给管理医师带来了一些临床问题。目前,该病的治疗选择有限,其背后的证据基础薄弱。内镜干预仅限于阻塞性狭窄相关疾病的患者,甚至肝移植都有复发的风险。处理此类患者时,对炎症性肠病,代谢性骨病和恶性肿瘤的监视至关重要。本文概述了这种疾病,并进一步关注当前的治疗方案和监测管理指南。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号